What the trial was testing
The XTEND-KIDS enrolled 74 patients with hemophilia. The study was sponsored by Bioverativ, a Sanofi company and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Sixty-four percent of kids had no bleeding episodes at all over the course of a year.
The New England journal of medicine · 2024 · NCT04759131
These findings — that no bleeding episodes for an entire year on weekly injections — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 74 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with hemophilia, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
If your child has severe hemophilia A, this once-a-week injection might mean far fewer bleeds and less time dealing with treatment. Most kids in this study didn't bleed at all. This treatment is FDA-approved and available now. Talk to your hematologist about whether it's right for your child.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open hemophilia trials
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
A non-randomized, open-label study to evaluate the safety, kinetics and efficacy of a single intravenous infusion of ZS801 in hemophilia B subjects with endogenous FIX ≤2%.
Tight Control of Treatment Adherence and Efficacy by Telemedicine for an Improved Personalized Management of Patients With Hemophilia
In patients with haemophilia, close monitoring of bleeding with optimal adherence to treatment, a personalised treatment programme and the possibility of early diagnosis of haemarthrosis are essential. The TEMPO project will help advance the state of the art in optimal adherence, rigorous monitoring, and accurate and early diagnosis and management of haemarthrosis by collecting and integrating big data in order to personalise the treatment regimen for each patient, as envisaged by the current model of personalised medicine.